- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04163081
Badanie INITIATE: Rozpoczęcie leczenia uzależnienia od nikotyny u palaczy przyjętych na oddziały ratunkowe (INITIATE)
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Evyanne Wooding, R.Kin
- Numer telefonu: 17596 613-696-7000
- E-mail: ewooding@ottawaheart.ca
Kopia zapasowa kontaktu do badania
- Nazwa: Chantelle Masterson, BPhil
- Numer telefonu: 19157 613-696-7000
- E-mail: cmasterson@ottawaheart.ca
Lokalizacje studiów
-
-
Ontario
-
Ottawa, Ontario, Kanada
- Rekrutacyjny
- University of Ottawa Heart Institute
-
Kontakt:
- Dr. Kerri-Anne Mullen
- Numer telefonu: 613-696-7000 ext.19095
- E-mail: KMullen@ottawaheart.ca
-
Ottawa, Ontario, Kanada
- Rekrutacyjny
- Civic Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Numer telefonu: 6137985555,17023
- E-mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutacyjny
- General Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Numer telefonu: 6137985555,17023
- E-mail: vthirug@toh.ca
-
Ottawa, Ontario, Kanada
- Rekrutacyjny
- Riverside Hospital
-
Kontakt:
- Dr. Venkatesh Thiruganasambandamoorthy
- Numer telefonu: 6137985555,17023
- E-mail: vthirug@toh.ca
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Current daily smoker (smokes ≥ 5 cigarettes per day);
- ≥ 18 years of age (the age of majority in Ontario);
- For ED sites only, assigned a CTAS level of 2-5 (emergent to non-urgent);
- Able to read and understand English or French;
- Resides in Ontario and eligible for Ontario Health Insurance Plan (to permit linkage with administrative data housed at the Institute for Clinical Evaluative Sciences [ICES]);
- Available and willing to participate in follow-up assessments over the next 12 months;
- Has access to a telephone or computer;
- Able to provide informed consent
Exclusion Criteria:
- Currently participating in this or another smoking cessation study;
- For ED sites only, assigned a CTAS level of 1 (resuscitation - the most seriously ill patients with highest likelihood of hospital admission) or in psychiatric emergency unit;
- Pregnant, planning to become pregnant over the next year, or breastfeeding;
- Has morbid illness which will prevent completion of 26-week follow-up (e.g., receiving palliative care);
- In the opinion of the attending physician, manifests acute physical and/or psychiatric illness or has cognitive impairment that would preclude participation in/benefit from the intervention.
- Scheduled for a known elected surgery, procedure, or future hospitalization during the study period.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Quit Card Intervention (QCI)
Study intervention group. |
The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a "Quit Card" (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist. |
|
Brak interwencji: Usual Care (UC)
Study control group. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Smoking Abstinence
Ramy czasowe: 26 weeks (6 months) after study enrollment
|
Smoking abstinence at 26 weeks, biochemically verified using an expired air carbon monoxide (CO) test |
26 weeks (6 months) after study enrollment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Prolonged Abstinence
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Prolonged (since last time point) smoking abstinence, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Point Prevalence Abstinence
Ramy czasowe: 4, and 52 weeks after study enrollment
|
Point prevalence smoking abstinence, at 4, and 52 weeks |
4, and 52 weeks after study enrollment
|
|
Smoking Reduction
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Smoking reduction (i.e., change in number of daily cigarettes), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Number of Quit Attempts
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Number of quit attempts since study entry, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cessation Medication and/or E-cigarette Use
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Use of smoking cessation medication and/or e-cigarette, at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Use of Behavioural Supports
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Use of behavioural supports (e.g., counseling, quit lines), at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health-Related Quality of Life
Ramy czasowe: 52 weeks after study enrollment
|
Health-related quality of life (HR-QoL), at 52 weeks. This will be measured using the Hospital Anxiety and Depression Scale (HADS), designed to identify and measure the levels of anxiety and depression among individuals in non-psychiatric hospital settings, and the Health Questionnaire Assessment (EQ-5D-5L), using five graded severity levels to summarize perceived health across five foundational dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. |
52 weeks after study enrollment
|
|
Health Services Outcomes - ED visits
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) visits to ED at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Hospital Admissions
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) admissions to hospital at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Health Services Outcomes - Deaths
Ramy czasowe: 4, 26, and 52 weeks after study enrollment
|
Number of all-cause and smoking-related (e.g., vascular, respiratory, cancer-related) deaths at 4, 26, and 52 weeks |
4, 26, and 52 weeks after study enrollment
|
|
Cost-Effectiveness Ratios
Ramy czasowe: 52 weeks after study enrollment
|
Cost-effectiveness ratios related to health services at 52 weeks |
52 weeks after study enrollment
|
Współpracownicy i badacze
Współpracownicy
Śledczy
- Główny śledczy: Kerri-Anne Mullen, PhD, Ottawa Heart Institute Research Corporation
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 20190485-01H
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .